Euroapi Company Header Euroapi Company Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Bioventure Healthcare.

    Client Virtual Booth

    BIOVENTURE HEALTHCARE

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Bioventure Healthcare
    saudiarabiapng-1555324364png-1605701218 Flag
    Country
    Country
    U.A.E
    Address
    Address
    Abu Dhabi, UAE – PO Box 5254
    Telephone
    Telephone
    +971 4 801 6000
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.bioventurehealthcare.ae
    Linkedin
    Linkedin
    https://www.linkedin.com/company/yasholding/
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) in Egypt

    Details:

    AVT02 (adalimumab-aqvh) is a monoclonal antibody which inhibits tumor necrosis factor. It binds specifically to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors.


    Lead Product(s): Adalimumab

    Therapeutic Area: Immunology Product Name: AVT02

    Highest Development Status: ApprovedProduct Type: Large molecule

    Recipient: Alvotech

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable August 29, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Bioventure, Minapharm Pharmaceuticals and MiGenTra Sign an Exclusive Agreement for the Commercialization of Multiple Biosimilar Candidates of Alvotech i...

    Details:

    Minapharm Pharmaceuticals and MiGenTra GmbH will share responsibilities in the Territory to file, launch and commercialize Alvotech's portfolio of licensed biosimilars once approved, under Bioventure's exclusive strategic partnership with Alvotech in the region.


    Lead Product(s): Undisclosed

    Therapeutic Area: Immunology Product Name: Undisclosed

    Highest Development Status: UndisclosedProduct Type: Large molecule

    Recipient: Minapharm Pharmaceuticals

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Agreement November 30, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    famar-2024-07-22

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search